Al Hamed R, Bazarbachi AH, Bazarbachi A, et al. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97.

Article  PubMed  PubMed Central  Google Scholar 

Toumaala H, Kärppä M, Tuominen H, Remes AM. Amyloid myopathy: a diagnostic challenge. Neurol Int. 2009;1(1):e7.

Article  Google Scholar 

Malek N, O'Donovan DG, Manji H. AL amyloidosis presenting with limb girdle myopathy. Pract Neurol. 2018;18(6):497-500.

Article  PubMed  Google Scholar 

Ghosh PS, Thaera GM, Tracy JA. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy. Neurology. 2013;81(24):e184.

Article  PubMed  Google Scholar 

Keith J, Afshar-Ghotli Z, Roussev R. Myopathy as the initial manifestation of primary amyloidosis. Can J Nerurol Sci. 2011;38(1):161-4.

Article  CAS  Google Scholar 

Rodolico C, Mazzeo A, Toscano A. Amyloid myopathy presenting with rhabdomyolysis: evidence of complement activation. Nruromuscul Disord. 2006; 16(8):514-7.

Article  CAS  Google Scholar 

Alenzi FM. Myositis Soecific Autoantibodies: A Clinical Perspective. Open Access Rheumatol. 2020:12:0–14.

Satoh M, Tanaka S, Ceribeli A, Calise SJ, Chan EK. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol. 2017 ;52(1):1-19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985(l);28:796–803.

Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70:360-74.

Article  CAS  PubMed  Google Scholar 

Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017; 76(12):1955-1964.

Article  PubMed  Google Scholar 

Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2017;88(5):493-500.

Article  CAS  PubMed  Google Scholar 

Tanboon J, Inoue M, Hirakawa S, et al. Pathologic Features of Anti-Mi-2 Dermatomyositis. Neurology. 2021;96(3): e448-e459.

Article  CAS  PubMed  Google Scholar 

Tanboon J, Inoue M, Saito Y, et al. Dermatomyositis: Muscle Pathology According to Antibody Subtypes. Neurology. 2022 Feb 15; 98(7):e739-e749.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanboon J, Inoue M, Hirakawa S, et al. Muscle pathology of antisynthetase syndrome according to antibody subtypes. Brain Pathol. 2023 Jul; 33(4)e13155.

Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 Jul 2;136(1):71-80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muchtar E, Derudas D, Mauermann M, et al. Systemic immunoglobulin light chain amyloidosis-associated myopathy: presentation, diagnostic pitfalls, and outcome. Mayo Clin Proc. 2016; 91(10):1354-1361.

Article  CAS  PubMed  Google Scholar 

Comesaña L, del Castillo M, Martín R, et al. Musculoskeletal amyloid disease: MRI features. Ann Radiol(Paris). 1995 ;38(3):150–2.

Hull KM, Griffith L, Kuncl RW, Wigley FM. A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features. Arthritis Rheum. 2001;44:1954-8.

Article  CAS  PubMed  Google Scholar 

Yata T, Miwa T, Araki K, et al. [A case of systemic AL amyloidosis diagnosed on muscle biopsy]. Rinsho Shinkeigaku. 2020 ;60(1):60-63.

Article  PubMed  Google Scholar 

Zhang Y, LeRoy G, Seelig HP, et al. The dermatomyositis-specific autoantigen Mi2 is component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell. 1998;95:279-89.

Article  CAS  PubMed  Google Scholar 

Anna G, Sandra Z, Luca I, et al. Anti-Mi-2 antibodies. Autoimmunity. 2005;38:79-83.

Article  Google Scholar 

Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889.

Article  CAS  PubMed  Google Scholar 

Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 ;57(5):664-78.

Article  CAS  PubMed  Google Scholar 

Ghirardello A, Zampieri S, Iacccarino L, et al. Anti-Mi-2 antibodies. Autoimmunity. 2005; 38(1):79-83.

Article  CAS  PubMed  Google Scholar 

Fujimoto M, Murakami A, Kurei S, et al. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. 2016; 84(3):272–281.

Muro Y, Sugiura K, Akiyama M. A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement. Clin Dev Immunol. 2013; 2013: 856815.

Article  PubMed  PubMed Central  Google Scholar 

Kuwana M, Okazaki Y. A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting. Mod Rheumatol. 2023 13;33(3):543–548.

Kawakami N, Katsuyama Y, Hagiwara Y, et al. A case of amyloid myopathy diagnosed during the treatment of myopathy associated with anti-signal recognition particle antibodies. Rinsho Shinkeigaku. 2017;57(4):168-173.

Article  PubMed  Google Scholar 

Ungprasert P, Leeaphorn Napat, Hosiriluck N, et al. Clinical features of inflammatory myopathies and their assocication with malignancy: a systematic review in Asian population. ISRN Rheumatol. 2013:1203:509354.

Parthiban GP, Wilson J, Nesheiwat J. Amyloid myopathy: a cunning masquerader. 2023; 15(5):e39576.

Google Scholar 

Moore S, Symmons DP, DuPlessis D, et al. Amyloid myopathy masquerading as polymyositis. Clin Exp Rheumatol. 2015; 33(4):590-1.

PubMed  Google Scholar